Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaron Beijing CoHKSE:03759 -0.17%93 Gross Margin % is 32.50% as of Mar. 2026, which is 8% below its 10-year median of 35.18. GuruFocus rates HKSE:03759 with a GF Score™ of 93/100 and a GF Value™ of HK$22.86 (Fairly Valued). The stock has 9 warning signs investors should review. Among 733 Biotechnology companies, Pharmaron Beijing Co ranks worse than 73.4% on this metric.
Pharmaron Beijing Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -1.5%.
The historical rank and industry rank for Pharmaron Beijing Co's Gross Margin % or its related term are showing as below:
HKSE:03759'
s Gross Margin % Range Over the Past 10 Years
Min: 29 Med: 35.18 Max: 37.47
Current: 34.51
During the past 12 years, the highestGross Margin % of Pharmaron Beijing Co was 37.47%. The lowest was 29.00%. And the median was 35.18%.
HKSE:03759's Gross Margin % is ranked worse than 73.4% of 733
companies
in the Biotechnology industry
Industry Median: 60.91
vs HKSE:03759: 34.51
Pharmaron Beijing Co had a gross margin of 32.50% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Pharmaron Beijing Co was -1.50% per year.
Pharmaron Beijing Co (HKSE:03759) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Pharmaron Beijing Co had a gross margin of 32.50% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Pharmaron Beijing Co Gross Margin % Related Terms
Pharmaron Beijing Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for Pharmaron Beijing Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:03759 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Pharmaron Beijing Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaron Beijing Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Pharmaron Beijing Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Pharmaron Beijing Co (HKSE:03759) has a Gross Margin % of 32.50% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Pharmaron Beijing Co and its competitors. This is near median its historical median of 35.18. Over the past decade, Pharmaron Beijing Co's Gross Margin % has ranged from 29.00 to 37.47. According to the industry distribution chart, Pharmaron Beijing Co ranks #538 out of 733 companies in the Biotechnology industry, placing it in the top 73.4%.
Is Pharmaron Beijing Co's Gross Margin % too high?
Pharmaron Beijing Co's current Gross Margin % of 32.50% is near median its 10-year median of 35.18. Over the past 10 years, this metric has ranged from a low of 29.00 to a high of 37.47. The Biotechnology industry median Gross Margin % is 60.91. Pharmaron Beijing Co's value of 32.50% is 46.6% below this industry median. Based on the distribution chart, Pharmaron Beijing Co ranks #538 out of 733 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pharmaron Beijing Co has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmaron Beijing Co ranks #538 out of 733 companies for Gross Margin %. This places Pharmaron Beijing Co in the lower half of its industry. The industry median Gross Margin % is 60.91. Pharmaron Beijing Co's value of 32.50% is 46.6% below this benchmark. Historically, Pharmaron Beijing Co's own Gross Margin % has ranged from 29.00 to 37.47 over the past decade. While the company's 10-year median is 35.18 vs. the industry median of 60.91, Pharmaron Beijing Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmaron Beijing Co's current Gross Margin % of 32.50% is 46.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Pharmaron Beijing Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaron Beijing Co's current Gross Margin % is 32.50%, which is near median its own 10-year median of 35.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Based on GuruFocus' analysis, Pharmaron Beijing Co (HKSE:03759) is currently considered Fairly Valued. The stock's GF Value™ is HK$22.86, compared to a current price of HK$23.66 — trading 3.5% above its estimated fair value. The current Gross Margin % is 32.50%, which is near median its 10-year median of 35.18 and 46.6% below the Biotechnology industry median of 60.91. Pharmaron Beijing Co's overall GF Score™ is 93/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Pharmaron Beijing Co (HKSE:03759), the current Gross Margin % is 32.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (HKSE:03759) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of HK$23.66 is trading 3.5% above its estimated GF Value™ of HK$22.86.
GuruFocus considers Pharmaron Beijing Co to be Fairly Valued.
Key valuation signals for HKSE:03759:
Gross Margin %: 32.50% (near median its 10-year median of 35.18)
GF Value™: HK$22.86 vs. price of HK$23.66 (3.5% above fair value)
Industry Position: 46.6% below the Biotechnology median (#538 of 733)
No single metric tells the full story. See the HKSE:03759 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
93GF Score
Get the complete analysis for HKSE:03759
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03759 has been successfully added to your 
